Skip to main content

Table 4 Treatments administered in ICU and outcomes

From: Seasonal burden of severe influenza virus infection in the critically ill patients, using the Assistance Publique-Hôpitaux de Paris clinical data warehouse: a pilot study

Variable All participants
n = 320
Survivors
n = 257
Non-survivors
n = 63
Organ support and additional therapies, n (%)
 Mechanical ventilationa 182 (56.9) 136 (52.9) 46 (73.0)
 Invasive mechanical ventilation 116 (36.2) 77 (30.0) 39 (61.9)
 Neuromuscular blocking agents 17 (5.3) 13 (5.1) 4 (6.3)
 Prone positioning 35 (10.9) 23 (8.9) 12 (19.0)
 NO 17 (5.3) 13 (5.1) 4 (6.3)
 ECMO 6 (1.9) 3 (1.2) 3 (4.8)
 Vasopressors 100 (31.2) 62 (24.1) 38 (60.3)
 Renal replacement therapy 39 (12.2) 22 (8.6) 17 (27)
 Steroidsb 67 (20.9) 52 (20.2) 15 (23.8)
 Oseltamivirc 278 (86.9) 232 (90.3) 46 (73.0)
Length of stay (days), median [IQR]
 ICU 8 [4–15] 8 [4–15] 7 [2–15.5]
 Hospital 15 [8–28] 16 [9–31] 10 [3.5–18.5]
  1. NO nitric oxide, ECMO extracorporeal membrane oxygenation
  2. aInvasive mechanical ventilation with endotracheal intubation, non-invasive positive pressure ventilation and high flow nasal oxygen therapies were included in the category mechanical ventilation
  3. bSteroids included hydrocortisone and methylprednisolone
  4. cOseltamivir was either continued (n = 76) or introduced within the first 24 h of ICU/ICW referral (n = 202)